

C Warren Olanow

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9588405/c-warren-olanow-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

134
papers

18,140
citations

53
h-index

134
g-index

150
ext. papers

20,936
ext. citations

10.7
avg, IF

6.59
L-index

#	Paper	IF	Citations
134	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. <i>Movement Disorders</i> , 2008 , 23, 2129-70	7	3156
133	Levodopa and the progression of Parkinson's disease. <i>New England Journal of Medicine</i> , 2004 , 351, 2498-508	59.8	1355
132	Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. <i>Nature Medicine</i> , 2008 , 14, 504-6	50.5	1209
131	A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. <i>Annals of Neurology</i> , 2003 , 54, 403-14	9.4	1206
130	A double-blind, delayed-start trial of rasagiline in Parkinson's disease. <i>New England Journal of Medicine</i> , 2009 , 361, 1268-78	59.2	694
129	Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. <i>Brain</i> , 2013 , 136, 2419-31	11.2	682
128	Pathophysiology of the basal ganglia in Parkinson's disease. <i>Trends in Neurosciences</i> , 2000 , 23, S8-19	13.3	573
127	The scientific and clinical basis for the treatment of Parkinson disease (2009). <i>Neurology</i> , 2009 , 72, S1-136	5	547
126	Understanding cell death in Parkinson's disease. <i>Annals of Neurology</i> , 1998 , 44, S72-84	9.4	530
125	Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. <i>Lancet Neurology</i> , 2010 , 9, 1164-1172	24.1	498
124	Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. <i>Lancet Neurology</i> , 2014 , 13, 141-9	24.1	425
123	Failure of the ubiquitin-proteasome system in Parkinson's disease. <i>Nature Reviews Neuroscience</i> , 2001 , 2, 589-94	13.5	416
122	Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. <i>Lancet Neurology</i> , 2006 , 5, 677-87	24.1	396
121	Levodopa in the treatment of Parkinson's disease: current controversies. <i>Movement Disorders</i> , 2004 , 19, 997-1005	7	291
120	Targeting α -synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. <i>Lancet Neurology</i> , 2015 , 14, 855-866	24.1	286
119	Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. <i>Lancet</i> , 2014 , 384, 545-55	40	285
118	Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. <i>Movement Disorders</i> , 2013 , 28, 1064-71	7	283

117	Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. <i>Annals of Neurology</i> , 1998 , 44, S175-88	9.4	280
116	Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. <i>Annals of Neurology</i> , 2010 , 68, 18-27	9.4	270
115	Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?. <i>Movement Disorders</i> , 2013 , 28, 31-40	7	249
114	Lewy-body formation is an aggregates-related process: a hypothesis. <i>Lancet Neurology</i> , 2004 , 3, 496-503	24.1	235
113	Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. <i>Movement Disorders</i> , 1998 , 13, 383-93	7	232
112	Is Parkinson's disease a prion disorder?. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 12571-2	11.5	205
111	Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. <i>Annals of Neurology</i> , 2015 , 78, 248-57	9.4	190
110	Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. <i>Archives of Neurology</i> , 2005 , 62, 905-10		174
109	The pathogenesis of cell death in Parkinson's disease--2007. <i>Movement Disorders</i> , 2007 , 22 Suppl 17, S335-42	7	170
108	Ubiquitin-proteasome system and Parkinson's disease. <i>Movement Disorders</i> , 2006 , 21, 1806-23	7	153
107	TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. <i>Lancet Neurology</i> , 2006 , 5, 1013-20	24.1	144
106	The scientific basis for the current treatment of Parkinson's disease. <i>Annual Review of Medicine</i> , 2004 , 55, 41-60	17.4	143
105	A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. <i>Movement Disorders</i> , 2008 , 23, 2194-201	7	138
104	Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). <i>Clinical Neuropharmacology</i> , 2004 , 27, 58-62	1.4	135
103	Waking up to sleep episodes in Parkinson's disease. <i>Movement Disorders</i> , 2000 , 15, 212-5	7	128
102	Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. <i>Brain</i> , 2002 , 125, 2058-66	11.2	109
101	Therapeutic prospects for Parkinson disease. <i>Annals of Neurology</i> , 2013 , 74, 337-47	9.4	99
100	Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease. <i>Nature Clinical Practice Neurology</i> , 2006 , 2, 382-92		98

99	Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. <i>Lancet Neurology, The</i> , 2014 , 13, 767-76	24.1	97
98	Fetal Grafting for Parkinson's Disease: Expression of Immune Markers in Two Patients with Functional Fetal Nigral Implants. <i>Cell Transplantation</i> , 1997 , 6, 213-219	4	95
97	Clinical development of a poly(2-oxazoline) (POZ) polymer therapeutic for the treatment of Parkinson's disease [Proof of concept of POZ as a versatile polymer platform for drug development in multiple therapeutic indications. <i>European Polymer Journal</i> , 2017 , 88, 524-552	5.2	93
96	Why have we failed to achieve neuroprotection in Parkinson's disease?. <i>Annals of Neurology</i> , 2008 , 64 Suppl 2, S101-10	9.4	89
95	Dopamine agonists and neuroprotection in Parkinson's disease. <i>Annals of Neurology</i> , 1998 , 44, S167-74	9.4	85
94	Dopaminergic transplantation for Parkinson's disease: current status and future prospects. <i>Annals of Neurology</i> , 2009 , 66, 591-6	9.4	70
93	Tolcapone: an efficacy and safety review (2007). <i>Clinical Neuropharmacology</i> , 2007 , 30, 287-94	1.4	70
92	Levodopa: effect on cell death and the natural history of Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 37-44	7	69
91	Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. <i>Movement Disorders</i> , 2009 , 24, 336-43	7	68
90	Movement disorder society criteria for clinically established early Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 1643-1646	7	67
89	L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro. <i>Journal of Neurochemistry</i> , 1997 , 68, 33-9	6	67
88	COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications?. <i>Neurology</i> , 2004 , 62, S72-81	6.5	60
87	Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease. <i>Neurology</i> , 2006 , 66, S69-79	6.5	60
86	The significance of defining preclinical or prodromal Parkinson's disease. <i>Movement Disorders</i> , 2012 , 27, 666-9	7	59
85	The causes of Parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality. <i>Annals of Neurology</i> , 1998 , 44, S189-96	9.4	55
84	Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient. <i>Annals of Neurology</i> , 2017 , 81, 46-57	9.4	54
83	Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease. <i>Movement Disorders</i> , 2016 , 31, 1366-72	7	54
82	Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease. <i>Movement Disorders</i> , 2000 , 15, 485-489	7	54

81	Temporal evolution of microglia and β synuclein accumulation following foetal grafting in Parkinson's disease. <i>Brain</i> , 2019 , 142, 1690-1700	11.2	51
80	Can we achieve neuroprotection with currently available anti-parkinsonian interventions?. <i>Neurology</i> , 2009 , 72, S59-64	6.5	50
79	L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro. <i>Journal of Neurochemistry</i> , 1997 , 68, 434-6	6	50
78	Trophic factors for Parkinson's disease: To live or let die. <i>Movement Disorders</i> , 2015 , 30, 1715-24	7	47
77	Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. <i>Movement Disorders</i> , 2005 , 20 Suppl 11, S3-10	7	47
76	Levodopa: A new look at an old friend. <i>Movement Disorders</i> , 2018 , 33, 859-866	7	46
75	Levodopa/dopamine replacement strategies in Parkinson's disease--future directions. <i>Movement Disorders</i> , 2008 , 23 Suppl 3, S613-22	7	46
74	Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Neurology</i> , 2020 , 19, 135-144	24.1	42
73	Parkinsonism associated with Sjögren's syndrome: three cases and a review of the literature. <i>Movement Disorders</i> , 1999 , 14, 262-8	7	41
72	Glial cells mediate toxicity in glutathione-depleted mesencephalic cultures. <i>Journal of Neurochemistry</i> , 1999 , 73, 112-9	6	38
71	Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease. <i>Brain</i> , 2020 , 143, 960-975	11.2	37
70	Long-term effects of rasagiline and the natural history of treated Parkinson's disease. <i>Movement Disorders</i> , 2016 , 31, 1489-1496	7	35
69	Parkinson's disease, proteins, and prions: milestones. <i>Movement Disorders</i> , 2011 , 26, 1056-71	7	33
68	Defining disease-modifying therapies for PD--a road map for moving forward. <i>Movement Disorders</i> , 2010 , 25, 1774-9	7	28
67	Do prions cause Parkinson disease?: the evidence accumulates. <i>Annals of Neurology</i> , 2014 , 75, 331-3	9.4	27
66	The delayed-start study in Parkinson disease: can't satisfy everyone. <i>Neurology</i> , 2010 , 74, 1149-50	6.5	20
65	Continuous Dopaminergic Stimulation as a Treatment for Parkinson's Disease: Current Status and Future Opportunities. <i>Movement Disorders</i> , 2020 , 35, 1731-1744	7	20
64	Targeting β synuclein as a therapy for Parkinson's disease: The battle begins. <i>Movement Disorders</i> , 2017 , 32, 203-207	7	17

63	The role of dopamine agonists in the treatment of early Parkinson's disease. <i>Neurology</i> , 2002 , 58, S33-41	6.5	17
62	Milestones in movement disorders clinical trials: advances and landmark studies. <i>Movement Disorders</i> , 2011 , 26, 1003-14	7	14
61	Dietary vitamin E and Parkinson's disease: something to chew on. <i>Lancet Neurology</i> , 2003 , 2, 74	24.1	13
60	Once-Weekly Subcutaneous Delivery of Polymer-Linked Rotigotine (SER-214) Provides Continuous Plasma Levels in Parkinson's Disease Patients. <i>Movement Disorders</i> , 2020 , 35, 1055-1061	7	12
59	Present and future directions in the management of motor complications in patients with advanced PD. <i>Neurology</i> , 2003 , 61, S24-33	6.5	12
58	Levodopa therapy for Parkinson's disease: challenges and future prospects. <i>Movement Disorders</i> , 2008 , 23 Suppl 3, S495-6	7	10
57	Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study. <i>Journal of Parkinson's Disease</i> , 2021 , 11, 177-186	5.3	10
56	Parkinson disease: Gene therapy for Parkinson disease--a hope, or a dream?. <i>Nature Reviews Neurology</i> , 2014 , 10, 186-7	15	9
55	Advances in clinical trials for movement disorders. <i>Movement Disorders</i> , 2015 , 30, 1580-7	7	8
54	Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study. <i>Journal of Huntington's Disease</i> , 2020 , 9, 371-380	1.9	8
53	Reply: Levodopa in the treatment of Parkinson's disease: Current controversies. <i>Movement Disorders</i> , 2005 , 20, 643-644	7	7
52	Speech and Voice Disorders in Parkinson's Disease 2011 , 346-360		6
51	Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study. <i>Movement Disorders</i> , 2019 , 34, 425-429	7	6
50	Initiating levodopa therapy for Parkinson's disease. <i>Movement Disorders</i> , 2014 , 29, 430	7	5
49	Reply to Montgomery. <i>Annals of Neurology</i> , 2009 , 65, 618-619	9.4	4
48	Movement disorders: a step in the right direction. <i>Lancet Neurology</i> , 2006 , 5, 3-5	24.1	4
47	A New Approach to the Development of Disease-Modifying Therapies for PD; Fighting Another Pandemic. <i>Movement Disorders</i> , 2021 , 36, 59-63	7	3
46	On-Demand Therapy for OFF Episodes in Parkinson's Disease. <i>Movement Disorders</i> , 2021 , 36, 2244-2253	7	3

45	Subcutaneous Levodopa Infusion for Parkinson's Disease: 1-Year Data from the Open-Label BeyoND Study. <i>Movement Disorders</i> , 2021 , 36, 2687-2692	7	3
44	Non-Dopaminergic Pathology of Parkinson's Disease15-31		3
43	The vatican meeting on neuroprotection for Parkinson's disease. <i>Movement Disorders</i> , 2013 , 28, 1-2	7	2
42	Pain and Paresthesia in Parkinson's Disease 2011 , 315-332		2
41	Profile of Mahlon DeLong and Alim Benabid, 2014 Lasker-DeBakey Medical Research awardees. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 17693-5	11.5	1
40	Dopamine Dysregulation Syndrome 2011 , 202-214		1
39	Clinical Features of Dementia Associated with Parkinson's Disease and Dementia with Lewy Bodies 2011 , 134-144		1
38	Anxiety Syndromes and Panic Attacks 2011 , 193-201		1
37	Neuronal Mechanisms of REM Sleep and their Role in REM Sleep Behavior Disorder 2011 , 240-245		1
36	The Emerging Entity of Pre-Motor Parkinson's Disease 2011 , 93-104		1
35	Dose optimization of apomorphine sublingual film for treating "OFF" episodes in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021 , 93, 27-30	3.6	1
34	Gait, Postural Instability, and Freezing261-373		1
33	Neuropathologic Involvement of the Dopaminergic Neuronal Systems in Parkinson's Disease7-14		1
32	Movement Disorders Journal: Yesterday, Today, Tomorrow, and Always. <i>Movement Disorders</i> , 2019 , 34, 1814-1816	7	1
31	Adverse event reporting in clinical trials in Parkinson's Disease: Time for change. <i>Movement Disorders</i> , 2018 , 33, 1685-1687	7	1
30	The Dopaminergic and Non-Dopaminergic Features of Parkinson's Disease1-6		1
29	Effects of Exercise on Basal Ganglia Function in Parkinson's Disease and Its Animal Models416-431		1
28	Bladder Dysfunction in Parkinson's Disease and Other Parkinsonism274-283		0

- 27 Non-Dopaminergic Approaches to the Treatment of Parkinson's Disease **2011**, 432-454
- 26 Overview of the Medical Treatment of the Non-Motor and Non-Dopaminergic Features of Parkinson's Disease **2011**, 394-408
- 25 Sleep Disorders in Parkinson's Disease **2011**, 233-239
- 24 Psychosis in Parkinson's Disease **2011**, 170-182
- 23 Depression in Parkinson's Disease **2011**, 183-192
- 22 Neurobiology of Impulse Control Disorders in Parkinson's Disease **2011**, 215-232
- 21 Orthopedic Complications of Parkinson's Disease **2011**, 374-386
- 20 Functional Imaging Studies in Parkinson's Disease: The Non-Dopaminergic Systems **2011**, 105-110
- 19 Other Non-Motor Symptoms of Parkinson's Disease **2011**, 387-393
- 18 The Etiopathogenesis of Parkinson's Disease: Basic Mechanisms of Neurodegeneration **2008**, 1-23
- 17 REM Sleep Behavior Disorder and Neurodegenerative Disorders 246-256
- 16 Restless Legs Syndrome and Akathisia in Parkinson's Disease 333-345
- 15 Assessment of Non-Motor Features of Parkinson's Disease: Scales and Rating Tools 111-125
- 14 Neuropsychologic Features of Parkinson's Dementias 145-152
- 13 Sexual Dysfunction 296-303
- 12 Anatomy and Physiology of Limbic System Dysfunction in Parkinson's Disease 70-78
- 11 Orthostatic Hypotension in Parkinson's Disease 284-295
- 10 Prospects for Neuroprotective Therapies that can Modulate Non-Dopaminergic Features in Parkinson's Disease 455-461

- 9 Surgery for Non-Dopaminergic and Non-Motor Features of Parkinson's Disease 409-415
- 8 Olfactory Dysfunction 304-314
- 7 Functional Organization of the Basal Ganglia: Dopaminergic and Non-Dopaminergic Features 56-69
- 6 Functional Anatomy of the Motor and Non-Motor Circuitry of the Basal Ganglia 32-55
- 5 Animal Models of Parkinson's Disease: The Non-Motor and Non-Dopaminergic Features 79-92
- 4 Neuropathology of Dementia in Parkinson's Disease 153-162
- 3 Gastrointestinal and Swallowing Disturbances in Parkinson's Disease 257-273
- 2 Clinical Trial Measures of the Non-Motor Features of Parkinson's Disease 126-133
- 1 Treatment of Dementia Associated with Parkinson's Disease 163-169